Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 26.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (9.1%)
  • Dividend yield for the last twelve months 3.4%
  • Free cash flow yield 0.2% (LTM)
  • Share price is 28.5% higher than minimum and 29.0% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (9.9x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $1.3 mln (-0.001% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (-0.7%)94.43
year average price 87.14  


year start price 99.86 2024-11-21

max close price 103.79 2024-12-09

min close price 73.47 2025-05-14

current price 94.43 2025-11-20
Common stocks: 2 528 810 012

Dividend Yield:  3.4%
FCF Yield LTM: 0.2%
EV / LTM EBITDA: 9.9x
EV / EBITDA annualized: 8.3x
Last revenue growth (y/y):  +3.7%
Last growth of EBITDA (y/y):  +49.7%
Historical revenue growth:  +3.0%
Historical growth of EBITDA:  +15.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 238 796
Net Debt ($m): 23 217
EV (Enterprise Value): 262 013
EBITDA LTM ($m): 26 386
EV / LTM EBITDA: 9.9x
Price to Book: 4.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-20seekingalpha.com

Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-20zacks.com

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

2025-11-20zacks.com

Here's Why Merck (MRK) is a Strong Value Stock

2025-11-19businesswire.com

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection

2025-11-19businesswire.com

European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union

2025-11-18businesswire.com

Merck Announces First-Quarter 2026 Dividend

2025-11-18businesswire.com

Merck's WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)

2025-11-18seekingalpha.com

Merck Has Many Bullish Attributes (Technical Analysis)

2025-11-17zacks.com

MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026

2025-11-17zacks.com

MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data